Stifel Nicolaus Cuts Endologix, Inc. (ELGX) Price Target to $5.50
Endologix, Inc. (NASDAQ:ELGX) had its target price trimmed by Stifel Nicolaus from $6.00 to $5.50 in a research report released on Wednesday. The firm currently has a hold rating on the medical instruments supplier’s stock.
A number of other brokerages have also recently weighed in on ELGX. Royal Bank Of Canada decreased their price objective on Endologix from $5.00 to $4.00 and set a sector perform rating for the company in a research note on Wednesday. Canaccord Genuity reiterated a hold rating and issued a $5.00 price target on shares of Endologix in a research note on Monday, October 9th. Zacks Investment Research cut Endologix from a strong-buy rating to a hold rating in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. set a $5.00 price target on Endologix and gave the company a hold rating in a research note on Thursday, August 3rd. Finally, ValuEngine cut Endologix from a sell rating to a strong sell rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and eleven have issued a hold rating to the stock. The stock currently has an average rating of Hold and an average target price of $6.13.
Shares of Endologix (ELGX) traded up $0.07 during midday trading on Wednesday, hitting $5.06. The company had a trading volume of 695,200 shares, compared to its average volume of 619,033. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.12. Endologix has a 1 year low of $4.08 and a 1 year high of $10.36.
COPYRIGHT VIOLATION WARNING: “Stifel Nicolaus Cuts Endologix, Inc. (ELGX) Price Target to $5.50” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/12/stifel-nicolaus-cuts-endologix-inc-elgx-price-target-to-5-50.html.
Large investors have recently made changes to their positions in the company. Kopp Investment Advisors LLC raised its stake in shares of Endologix by 11.5% in the second quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 2,270 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of Endologix in the second quarter worth about $111,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Endologix in the second quarter worth about $142,000. UBS Asset Management Americas Inc. raised its stake in shares of Endologix by 128.1% in the second quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the medical instruments supplier’s stock worth $170,000 after purchasing an additional 19,600 shares during the last quarter. Finally, Voya Investment Management LLC raised its stake in shares of Endologix by 16.4% in the second quarter. Voya Investment Management LLC now owns 38,910 shares of the medical instruments supplier’s stock worth $189,000 after purchasing an additional 5,471 shares during the last quarter.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Stock Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related stocks with our FREE daily email newsletter.